LONDON – Genmab A/S welcomed the announcement that partner Glaxosmithkline plc (GSK) is selling the rights to Arzerra (ofatumumab) in autoimmune diseases for $1.034 billion, saying the new owner, Novartis AG, has greater commitment to this field.